Leukocytoclastic Vasulitis Induced by Gefitinib.
- Author:
Jin Woo HONG
1
;
Su Young JEON
;
Ki Yeol LEE
;
Ki Hoon SONG
;
Ki Ho KIM
;
Young Hun KIM
Author Information
1. Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea. mucca@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Gefitinib;
Iressa(R);
Leukocytoclastic vasculitis
- MeSH:
Epidermal Growth Factor;
Exanthema;
Eye;
Hair;
Humans;
Hyperpigmentation;
Incidence;
Lung Neoplasms;
Mucous Membrane;
Nails;
Phosphotransferases;
Pruritus;
Quinazolines;
Skin;
Vasculitis;
Vasculitis, Leukocytoclastic, Cutaneous
- From:Korean Journal of Dermatology
2011;49(1):50-52
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Gefitinib (Iressa(R), AstraZeneca) is an oral form of an anticancer drug called epidermal growth factor receptor-tyrosine kinase inhibitor. It is widely used for various solid cancers, including lung cancer. Cutaneous adverse reactions induced by gefitinib have recently been reported with an incidence ranging from 49% to 100%, and they include acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail change and disorders of the mucous membranes, eyes and hair. To the best of our knowledge, no cases of leukocytoclastic vasculitis associated with gefitinib have ever been published in the Korean medical literature, and there have been only four such reported cases in other countries. Herein, we report on a case of leukocytoclastic vasulitis induced by gefitinib in a patient with lung cancer.
